In a single arm trial, Alumkal et al. carried out the efficacy, safety, pharmacokinetics, and pharmacodynamics study of SFN-rich broccoli sprout extracts (200 μmoles/day) administrated for 20 weeks in patients (20) with biochemical (PSA) recurrent prostate cancer. This evidence concerns the gene KLK3 and prostate carcinoma.